Latest Lotus Cars Stories
BEIJING, Sept. 23 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that the Company has appointed Mr. Xing Shen as its Vice President of Corporate Development and Ms. Yan Zeng as its Chief Financial Officer. Ms. Zeng, who served as CFO of Lotus in 2009 and early 2010, will relieve...
BEIJING, Sept. 9 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that the Company has appointed Jeff Hon as its new Chief Financial Officer. "We are excited to welcome Mr. Hon to our executive team," said the Company's Chairman and Chief Executive Officer, Dr. Zhongyi Liu....
BEIJING, Sept. 8 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that it has engaged RedChip Companies, Inc., to lead its public and investor relations efforts. "RedChip's integrity, professionalism, and established reputation for improving investor visibility in the small-cap space prompted...
BEIJING, Aug. 26 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC"), announced today that it has entered R-Bambuterol(R) Clinical Trial I on-schedule and is on-track to complete in six months. The studies will evaluate the safety and tolerability of the new drug as well as the biological activity by measuring...
BEIJING, Aug. 3 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC"), announced today that it has completed production of active pharmaceutical ingredient ("API") and tablets of R-Bambuterol for use in clinical trials according to China's State Food & Drug Administration ("SFDA")'s stringent regulations with...
BEIJING, July 22 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC"), announced today that it has entered into a termination agreement with Yorkville Global Master SPV Ltd. ("Yorkville") whereby the parties agreed to mutually terminate the Standby Equity Distribution Agreement, dated March 3, 2010, between the...
BEIJING, July 7 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC"), today announced it will present at the Global Hunter Securities 2010 China Conference held July 11-13, 2010 in San Francisco, California. Presentation details are noted below. Date: Monday, July 12, 2010 Time: 3:30 PM...
BERLIN and SAN FRANCISCO, June 8 /PRNewswire-FirstCall/ -- IBM (NYSE: IBM) today announced an expansion of IBM Lotus messaging and collaboration software with the delivery of secure enterprise mail for the Apple iPad. The news was announced at both the Deutsche Notes User Group in Berlin and the Apple Developers Conference in San Francisco. (Photo: http://photos.prnewswire.com/prnh/20100608/NY17116) (Photo: http://www.newscom.com/cgi-bin/prnh/20100608/NY17116) (Logo:...
BEIJING, April 29 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC") today reported that its innovative asthma drug Laevo-Bambuterol has received approval from China's State Food & Drug Administration's (SFDA) to commence clinical trials (No.2010L01309 and 2010L01399). R-Bambuterol(R) Hydrochloride...
TORONTO, April 22 /PRNewswire-FirstCall/ -- Tungle, the company that makes scheduling meetings easy, announced today the availability of its Tungle.me software for IBM's (NYSE: IBM) Lotus Notes collaboration software at the Lotusphere Comes to You conference in Toronto. The application will be introduced and demonstrated on stage today by Tungle CEO Marc Gingras and IBM Software Group Director of Messaging, Ed Brill. (Photo: http://www.newscom.com/cgi-bin/prnh/20100422/NY90995 )...
